Cancer
We’re investigating the biological basis of many solid and blood borne malignancies, advancing diagnosis, developing and trialing new therapies, and improving all aspects of the management of cancer including palliative care.
Do you have Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation?
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation.
Do you have newly diagnosed with advanced follicular lymphoma?
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma
Do you have an advanced solid tumour?
This study will investigate the use of a new medicine called INX-315 which may be used in the future as a possible treatment for advanced solid tumours.
Do you have a confirmed advanced solid tumor?
A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and cohort expansion study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of IOS-1002 administered alone and in combination with a PD-1 monoclonal antibody in advanced solid tumors.
Do you have muscle-invasive Bladder Cancer?
The trial is testing a potential new treatment for Muscle-invasive Bladder Cancer.
Do you have early breast cancer, and have had complete surgical removal of your tumour?
Evaluating the efficacy and safety of post surgical Giredestrant compared with doctors choice of endocrine therapy (Tamoxifen, Anastrozole, Letrozole or Exemestane) in patients with estrogen receptor−positive, HER2-negative early breast cancer.
Do you have gynaecological cancer with hormone receptor positive disease?
This trial is for people with gynaecological cancers whose tumours are potentially treatable with endocrine treatment.
Do you have Muscle-invasive Bladder Cancer?
The trial is testing a potential new treatment called disitamab vedotin for Muscle-invasive Bladder Cancer.
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML
Do you have Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression?